Recruiting

Ephedrine, Phenylephrine, Norepinephrine, Vasopressin

Sponsor:

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Code:

NCT04053478

Conditions

Hypotension

Eligibility Criteria

Sex: Female

Age: 19 - 40

Healthy Volunteers: Accepted

Interventions

Ephedrine

Phenylephrine

Norepinephrine

Vasopressin

Study Details

Brief summary:

Hypotension is one of the most common adverse effects of spinal anesthesia for cesarean deliveries, affecting as many as 55-90% of mothers. Hypotension during cesarean deliveries can have detrimental effects on the mother and neonate. Various vasopressors, such as ephedrine, phenylephrine and more recently norepinephrine, have been used for the prevention and treatment of hypotension at cesarean deliveries.

Ephedrine was historically considered as the gold standard vasopressor for the management of hypotension during cesarean deliveries. This was based on studies in animal models that showed preserved uteroplacental circulation with ephedrine and not with phenylephrine. However, multiple studies in the past several decades have shown that phenylephrine compared with ephedrine results in a more favorable fetal acid-base status. Consequently, the use of phenylephrine for blood pressure management during cesarean deliveries increased. Recently, norepinephrine was introduced in the obstetrical practice for the management of hypotension at cesarean deliveries, due to its ability to maintain maternal cardiac output better than phenylephrine.

Studies have also investigated the use of vasopressin to limit hypotension during CD. There have been case reports of successful vasopressin usage to treat post-spinal hypotension after CD in patients with advanced idiopathic pulmonary arterial hypertension as well as severe mitral stenosis with pulmonary hypertension. Its effect was associated with hemodynamic stability without evidence of harm to the mother or child. However, much controversy still exists surrounding the choice of vasopressor in the obstetric population, in large part due to their varying efficacies, and maternal and fetal effects.

Vasopressors used for the treatment of hypotension during cesarean deliveries can have significant direct or indirect effects on the perfusion of uteroplacental and umbilical vessels. Reduction of uteroplacental perfusion and constriction of umbilical vessels can result in fetal acidosis, however, the mechanisms for these effects are unclear. The investigators hypothesize that ephedrine, phenylephrine and norepinephrine and vasopressin have variable effects on the contractility of pregnant myometrium and umbilical arteries due to their variable actions on adrenergic alpha (α) and beta (β) receptors, as well as vasopressin1 and vasopressin2 receptors located in these tissues.

Conditions

Hypotension

Study ID

NCT04053478

Start date

Jul 8, 2019

Status verified date

Mar, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 19 - 40

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Patients who give written consent to participate in this study
  • Patients with gestational age 37-41 weeks
  • Patients of 19-40 years
  • Non-laboring patients, not exposed to exogenous oxytocin
  • Patients requiring elective primary or first repeat caesarean delivery
  • Patients undergoing caesarean delivery under spinal anesthesia

Exclusion Criteria:

  • Patients who refuse to give written informed consent
  • Patients who require general anesthesia
  • Patients in labor and those receiving oxytocin for induction of labor
  • Emergency caesarean delivery in labor
  • Patients who have had previous uterine surgery or >1 previous caesarean delivery
  • Patients with any condition predisposing to uterine atony
  • Patients on medications that could affect myometrial contractility, such as insulin, nifedipine, labetolol or magnesium sulfate.

Study Design

Enrollment

144 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Myometrium + Ephedrine

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

experimental: Myometrium + Phenylephrine

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

experimental: Myometrium + Norepinephrine

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

experimental: Myometrium + Vasopressin

The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

experimental: Umbilical artery + Ephedrine

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

experimental: Umbilical artery + Phenylephrine

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

experimental: Umbilical artery + Norepinephrine

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

experimental: Umbilical artery + Vasopressin

The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

experimental: Umbilical vein + Ephedrine

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

experimental: Umbilical vein + Phenylephrine

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

experimental: Umbilical vein + Norepinephrine

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

experimental: Umbilical vein + Vasopressin

The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

Interventions

Ephedrine

Ephedrine in solution, at applicable concentrations based on literature

Phenylephrine

Phenylephrine, at applicable concentrations based on literature

Norepinephrine

Norepinephrine, at applicable concentrations based on literature

Vasopressin

Vasopressin, at applicable concentrations based on literature

Primary outcome measure

  • Motility index [ Time Frame: 4 hours ]

Central Contacts and Locations

Central contacts

Locations

Mount Sinai Hospital

Recruiting

Toronto, Ontario, Canada, M5G1X5

Contacts

More Information

Sponsor

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Last update posted

Apr 6, 2026

Last verified

Mar, 2026

Keywords

  • vasopressor
  • ephedrine
  • phenylephrine
  • norepinephrine
  • umbilical arteries
  • uterine contraction
  • fetal acidosis
  • vasopressin

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Samuel Lunenfeld Research Institute, Mount Sinai Hospital on 2026-04-06.